domingo, 4 de agosto de 2024

FDA Calls AstraZeneca's NSCLC Trial Design Into Question M. Alexander Otto, PA, MMS

https://www.medscape.com/viewarticle/fda-calls-astrazenecas-nsclc-trial-design-question-2024a1000dw1

No hay comentarios:

Publicar un comentario